Clinical application of FDG-PET for cancer diagnosis

Nippon Acta Radiologica

Volumn 63, Issue 6, 2003, Pages 285-293

  Yuji, Nakamoto ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Clinical application; FDG; Limitation; PET; Role

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM; REVIEW; SCINTISCANNING; STANDARD;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141611174     PISSN: 00480428     EISSN: 13477951     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359: 1388-1393, 2002
2. Kubota K, Matsuzawa T, Fujiwara T, et al: Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 31: 1927-1932, 1990
3. Patz EF Jr, Lowe VJ, Hoffman JM, et al: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188: 487-490, 1993
4. Lowe VJ, Fletcher JW, Gobar L, et al: Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16: 1075-1084, 1998
5. Wahl RL, Quint LE, Greenough RL, et al: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191: 371-377, 1994
6. Steinert HC, Hauser M, Allemann F, et al: Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 202: 441-446, 1997
7. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212: 803-809, 1999
8. Kitagawa Y, Sadato N, Azuma H, et al: FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 40: 1132-1137, 1999
9. 18F] -2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27: 731-743, 2000
10. 18F-FDG PET. J Nucl Med 43: 1304-1309, 2002
11. Ito K, Kato T, Tadokoro M, et al: Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 182: 549-552, 1992
12. Flamen P, Stroobants S, Van Cutsem E, et al: Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D- glucose in recurrent colorectal cancer. J Clin Oncol 17: 894-901, 1999
13. Arulampalam T, Costa D, Visvikis D, et al: The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 28: 1758-1765, 2001
14. Tanaka T, Kawai Y, Kanal M, et al: Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg 184: 433-436, 2002
15. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al: Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110: 130-139, 1995
16. Higashi K, Matsunari I, Ueda Y, et al: Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 17: 1-14, 2003
17. Flamen P, Lerut A, Van Cutsem E, et al: The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120: 1085-1092, 2000
18. Nakamoto Y, Saga T, Ishimori T, et al: Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 176: 1449-1454, 2001
19. Torizuka T, Nobezawa S, Kanno T, et al: Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 29: 797-803, 2002
20. 18F-FDG PET in patients with cervical cancer. J Nucl Med 44: 347-352, 2003
21. Kole AC, Nieweg OE, Pruim J, et al: Detection of unkown occult primary tumors using positron emission tomography. Cancer 82: 1160-1166, 1998
22. Greven KM, Keyes JW Jr, Williams DW 3rd, et al: Occult primary tumor of the head and neck: lack of benefit from positron emission tomography imaging with 2- [F-18] fluoro-2-deoxy-D-glucose. Cancer. 86: 114-118, 1999
23. Bohuslavizki KH, Klutmann S, Kroger S, et al: FDG PET detection of unknown primary tumors. J Nucl Med 41: 816-822, 2000
24. 18F-fluorodeoxyglucose positron-emission tomography. Lancet 350: 1819, 1997
25. Yasuda S, Ide M, Fujii H, et al: Application of positron emission tomography imaging to cancer screening. Br J Cancer 83: 1607-1611, 2000
26. Cook GJ, Fogelman I, and Maisey MN: Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26: 308-314, 1996
27. Shreve PD, Anzai Y, and Wahl RL: Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19: 61-77, 1999
28. Rege SD, Chaiken L, Hoh CK, et al: Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 189: 807-812, 1993
29. Uematsu H, Sadato N, Yonekura Y, et al: Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. J Nucl Med 39: 2121-2127, 1998
30. Kawabe J, Okamura T, Shakudo M, et al: Physiological FDG uptake in the palatine tonsils. Ann Nucl Med 15: 297-300, 2001
31. Yasuda S, Shohtsu A, Ide M, et al: Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 207: 775-778, 1998
32. Chander S, Meltzer CC, and McCook BM: Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med 27: 22-24, 2002
33. 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44: 353-358, 2003
34. Miraldi F, Vesselle H, Faulhaber PF, et al: Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23: 3-7, 1998
35. Jadvar H, Schambye RB, and Segall GM: Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med 24: 965-967, 1999
36. Hustinx R, Smith RJ, Benard F, et al: Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26: 1345-1348, 1999
37. Boerner AR, Weckesser M, Herzog H, et al: Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 26: 226-230, 1999
38. Nakamoto Y, Higashi T, Sakahara H, et al: Delayed (18) F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89: 2547-2554, 2000
39. Kubota K, Itoh M, Ozaki K, et al: Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 28: 696-703, 2001
40. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43: 871-875, 2002
41. Kubota R, Yamada S, Kubota K, et al: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972-1980, 1992
42. Shreve PD: Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 25: 259-264, 1998
43. Sugawara Y, Braun DK, Kison PV, et al: Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 25: 1238-1243, 1998
44. Stahl A, Ott K, Weber WA, et al: FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30: 288-295, 2003
45. 18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 69: 117-124, 2003
46. Rohren EM, Provenzale JM, Barboriak DP, et al: Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 226: 181-187, 2003
47. Beyer T, Townsend DW, Brun T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 41: 1369-1379, 2000
48. 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging 29: 346-350, 2002
49. Nakamoto Y, Osman M, Cohade C, et al: PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med 43: 1137-1143, 2002
50. Goerres GW, Burger C, Kamel E, et al: Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology 226: 906-910, 2003
51. Osman MM, Cohade C, Nakamoto Y, et al: Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 44: 240-243, 2003
52. Nakamoto Y, Tatsumi M, Cohade C, et al: Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. Eur J Nucl Med Mol Imaging 30: 597-602, 2003
53. Cohade C, Osman M, Nakamoto Y, et al: Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med 44: 412-416, 2003